Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
certepetide + gemcitabine + nab-paclitaxel
- Development stage
- Phase 2
- Lead developer
- Lisata Therapeutics
- Modality
- Small Molecules, Peptides, Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
Certepetide + gemcitabine + nab-paclitaxel is a three-drug combination regimen investigated primarily for the first-line treatment of advanced or metastatic pancreatic ductal adenocarcinoma (PDAC). **Certepetide** (also known by code names LSTA1 or CEND-1) is a novel cyclic peptide that selectively targets tumor vasculature and stroma, enhancing the uptake and penetration of co-administered anticancer drugs into tumors. *Gemcitabine* is a nucleoside analog that inhibits DNA synthesis, functioning as a cytotoxic antimetabolite. *Nab-paclitaxel* is a nanoparticle albumin-bound formulation of paclitaxel, a microtubule stabilizer, which enhances tumor delivery by exploiting albumin-mediated transport pathways. Together, the combination aims to improve outcomes over standard gemcitabine plus nab-paclitaxel by increasing intratumoral drug concentrations, leading to enhanced antitumor effect. The combination is under investigation in phase II clinical studies for metastatic PDAC.
- Other names
- certepetide + nab-paclitaxel + gemcitabine
02
Targets
DCK (Deoxycytidine kinase)MicrotubuleTUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on certepetide + gemcitabine + nab-paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on certepetide + gemcitabine + nab-paclitaxel.